Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.50 |
| ▸ | AHCY | P23526 | 10/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5858366 | 0.89 | BCHE (0.51) | BCHEHSP90B1AHCYADORA2BADORA3 | |
| SCHEMBL2955999 | 0.88 | BCHE (0.42) | BCHEHSP90B1AHCYADORA2BADORA3 | |
| SCHEMBL5494937 | 0.88 | BCHE (0.47) | BCHEHSP90B1AHCYADORA2BADORA3 | |
| SCHEMBL112551 | 0.81 | ADORA3 (0.57) | AHCYADORA2BADORA3ADORA2A | |
| SCHEMBL7153500 | 0.81 | ADORA3 (0.57) | AHCYADORA2BADORA3ADORA2A | |
| SCHEMBL1980312 | 0.81 | ADORA3 (0.57) | AHCYADORA2BADORA3ADORA2A | |
| SCHEMBL9218734 | 0.80 | BCHE (0.51) | BCHEHSP90B1AHCYADORA2BADORA3 | |
| SCHEMBL5498025 | 0.79 | EHMT1 (0.50) | BCHEAHCYADORA2A | |
| SCHEMBL9856805 | 0.79 | P2RX3 (0.64) | — | |
| SCHEMBL21427226 | 0.77 | BCHE (0.55) | BCHEHSP90B1AHCYADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171126-A1 | Process for the production of purine nucleoside compounds | AJINOMOTO CO., INC. (JP) | 2005-08-04 | — | — | US | disclosed |
| EP-1550665-A1 | A process for the production of purine nucleoside compounds | Ajinomoto Co., Inc. (JP) | 2005-07-06 | — | — | EP | disclosed |
| US-5106962-A | Reacting nucleosides with viologens in the presence of base | AJINOMOTO CO., INC. (JP) | 1992-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171126-A1 | Process for the production of purine nucleoside compounds | PNP, NUDT1, UMPS | BCHE 871/4885HSP90B1 3906/4885AHCY 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.